Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Ribupatide

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Fujian Shengdi Pharmaceutical Co · Phase 3 · Completed · Enrollment 567

NCT06396429

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Treatment group A: HRS9531 injectionn/rn/rn/rn/r
Treatment group B: HRS9531 injectionn/rn/rn/rn/r
Treatment group C: HRS9531 injectionn/rn/rn/rn/r
Placebo injectionn/rn/rn/rn/r

Not shown

  • Treatment group A: HRS9531 injection: endpoint not reported
  • Treatment group B: HRS9531 injection: endpoint not reported
  • Treatment group C: HRS9531 injection: endpoint not reported
  • Placebo injection: endpoint not reported